About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Medicine still has many challenges to solve specially on complex diseases were a large number of both, genetic and environmental factors are involved. Among them, neurodegenerative and autoimmune disorders affecting the central nervous system have attracted attention because CNS is difficult to access and to manipulate with classical pharmacological treatments and, in addition, there are no effective curative treatments for these diseases. To address these problems, we have focused our research interests in gene therapy strategies for autoimmune diseases and neurodegenerative disorders specially those associated to aging.
The donation will support the continued development of a gene therapy strategy based on silencing the altered gene and restoring GNB1 protein function for the treatment of this ultra-rare encephalopathy.
The donation will enable further characterisation of patients with this rare disease, the identification of new biomarkers and the exploration of innovative therapies.
The Gen Rebelde Foundation has made the first donation of the year to the gene therapy research project for GNB1 encephalopathy.
Download the current rates for the services offered by the Gene Therapy at Nervous System research group. Check the historical rates in this link.
